Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the ...

Emerging research suggests reversible RNA editing mechanisms may influence heart disease biology while opening new avenues for biomarkers and next-generation cardiovascular therapies. Review: RNA ...

Wave Life Sciences (WVE) was not the only developer of RNA editing therapies to show significant stock gains from its historic proof-of-mechanism for its RNA editing platform, shown recently in the ...

This year marks the 25th anniversary of the publication of the Human Genome Project, a monumental scientific achievement that has transformed healthcare and laid the foundation for modern genomics.

A research team has uncovered new insights into the molecular mechanisms of ADAR1, a protein that regulates ribonucleic acid (RNA) induced immune responses. Their findings could open new pathways for ...

ProQR Therapeutics is advancing its Axiomer ADAR-mediated RNA editing pipeline, aiming to file a Clinical Trial Application for its lead program AX-0810, targeting NTCP for cholestatic diseases, by Q2 ...

ProQR Therapeutics advances RNA editing pipeline with upcoming CTA filing for AX-0810, while enhancing leadership and maintaining strong finances. ProQR Therapeutics N.V. announced significant ...